The UBC Department of Pediatrics invites applications for a Postdoctoral Research Fellow to join a multidisciplinary translational research program with specific goals to decipher the immune response to vaccination and infection in newborns.

The successful candidate will have been awarded the Ph.D degree within the past five years or within 10 years of being awarded the MD or DDS degree. Expertise in the field of immune phenotyping (flow cytometry; multiplex (Luminex) assessment of soluble markers), molecular biology (including systems biology/OMICS, including the bioinformatics necessary for optimal analysis), as well as in vitro experimentation is desirable. Experience with animal models (murine) is a requirement.

The applicant should also demonstrate the ability to work independently, supervise graduate and undergraduate students, conceive, initiate, organize and manage projects. Excellent verbal and written communication skills in English are a necessity as well as the ability to work in a team environment.

The position will begin ASAP. This is a one-year term appointment subject to annual renewal. Salary will be commensurate with qualifications and experience.

Please submit a letter of application, curriculum vitae, a statement of areas of expertise and strengths and the names of three referees, no later than 30 days after posting to Carolyn Smith (esmith@bcchr.ubc.ca; BCCH-RI A5-175, 950 W 28th Ave, Vancouver, BC V5Z4H4).

Principal Investigator//Supervisor:
Tobias R. Kollmann MD PhD; Professor of Pediatrics
Head (interim), Division of Pediatric Infectious Diseases, UBC

UBC hires on the basis of merit and is committed to employment equity. All qualified persons are encouraged to apply. We especially welcome applications from members of visible minority groups, women, Aboriginal persons, persons with disabilities, persons of minority sexual orientations and gender identities, and others with the skills and knowledge to engage productively with diverse communities. However, Canadians and permanent residents of Canada will be given priority.